In collaboration with neurologists and clinical research centres in
North America and Europe, TauRx is conducting a Phase 3 clinical trial, named
LUCIDITY. A recent change in the design of this trial expanded the number of patients from
375 to 450 and provided for a broader range of patients, including those
diagnosed with moderate Alzheimer’s disease, to be eligible for
participation. Patient recruitment for the LUCIDITY trial is underway across most of the sites. Of course, patient safety is our highest priority, and we are working closely with all sites to maintain patient safety in light of the Covid-19 pandemic.
The expanded trial uses well-accepted cognitive and functional assessment scales to confirm the potential benefits seen our lead compound, LMTX®, in delaying the progression of Alzheimer’s disease, and includes an open-label phase during which all participants will receive LMTX®. Patients completing the full trial will also be eligible for continued use of LMTX® under an expanded access programme.
For further information, and to understand the eligibility criteria for the LUCIDITY trial, or to find a site closest to you, please click here.
Additional information on the study is also available via this link
The company’s second-generation TAI, LMTX®, has now
completed three separate Phase 3 trials: two in Alzheimer's disease and
one in the rare neurodegenerative disorder, behavioural variant
frontotemporal dementia (bvFTD).